PPARγ in neuroblastoma

PPAR Research

Volumn , Issue , 2008, Pages

  Peri, Alessandro ^a   Cellai, Ilaria ^a   Benvenuti, Susanna ^a   Luciani, Paola ^a   Baglioni, Silvana ^a   Serio, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CIGLITAZONE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RISK; CHILDHOOD CANCER; HUMAN; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; REVIEW; XENOGRAFT;

EID: 45549085154     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/917815     Document Type: Review

References (78)

1. National Cancer Institute,. Surveillance, Epidemiology and End Results Database, November 2005, http://seer.cancer.gov
2. Maris J. M.
3. Brodeur G. M., Maris J. M., Pizzo P. A., Poplack D. G., Neuroblastoma Principles and Practice of Pediatric Oncology 2006 5th Philadelphia, Pa, USA JB Lippincott Company 933 970
4. Cheung N. K., Kushner B. H., LaQuaglia M., N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age Medical and Pediatric Oncology 2001 36 1 227 230
5. De Bernardi B.
6. Matthay K. K., Villablanca J. G., Seeger R. C., Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13- cis -retinoic acid The New England Journal of Medicine 1999 341 16 1165 1173
7. Wagner L. M.
8. Vassal G.
9. Saylors R. L. III, Stine K. C., Sullivan J., Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study Journal of Clinical Oncology 2001 19 15 3463 3469
10. Längler A., Christaras A., Abshagen K., Krauth K., Hero B., Berthold F., Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood-a phase-II-study Klinische Pädiatrie 2002 214 4 153 156
11. Tepmongkol S.
12. Matthay K. K.
13. Garaventa A., Bellagamba O., Lo Piccolo M. S., 131 I - metaiodobenzylguanidine (131I -MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients British Journal of Cancer 1999 81 8 1378 1384
14. Wiseman G. A., Kvols L. K., Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues Seminars in Nuclear Medicine 1995 25 3 272 278
15. O'Dorisio M. S., Hauger M., Cecalupo A. J., Somatostatin receptors in neuroblastoma: diagnostic and therapeutic implications Seminars in Oncology 1994 21 5 supplement 13 33 37
16. Borgström P., Hassan M., Wassberg E., The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo Pediatric Research 1999 46 3 328 332
17. Yu A. L.
18. Cheung N. K., Kushner B. H., Yeh S. D. J., Larson S. M., 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study International Journal of Oncology 1998 12 6 1299 1306
19. Kushner B. H., Kramer K., Cheung N.-K. V., Phase II trial of the anti- GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma Journal of Clinical Oncology 2001 19 22 4189 4194
20. Kang T. I., Brophy P., Hickeson M., Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma Journal of Pediatric Hematology/Oncology 2003 25 10 769 773
21. Howard J. P., Maris J. M., Kersun L. S., Tumor response and toxicity with multiple infusions of high dose 131I -MIBG for refractory neuroblastoma Pediatric Blood and Cancer 2005 44 3 232 239
22. DuBois S. G., Messina J., Maris J. M., Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma Journal of Clinical Oncology 2004 22 12 2452 2460
23. Neal Z. C., Yang J. C., Rakhmilevich A. L., Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy Clinical Cancer Research 2004 10 14 4839 4847
24. King D. M., Albertini M. R.
25. Yu A., Batova A., Strother D., Angelini P., Castleberry R. P., Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as vaccine for high risk neuroblastoma 75 Proceedings of the 11th Conference on Advances in Neuroblastoma Research (ANR '04) June 2004 Genoa, Italy
26. Gonzalez S., Naranjo A., Serrano L. M., Chang W.-C., Wright C. L., Jensen M. C.
27. Katzenstein H. M., Rademaker A. W., Senger C., Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden Clinical Cancer Research 1999 5 12 4273 4278
28. Shusterman S.
29. Wassberg E., Påhlman S., Westlin J.-E., Christofferson R., The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats Pediatric Research 1997 41 3 327 333
30. Nagabuchi E., VanderKolk W. E., Une Y., Ziegler M. M., TNP-470 antiangiogenic therapy for advanced murine neuroblastoma Journal of Pediatric Surgery 1997 32 2 287 293
31. Lode H. N., Moehler T., Xiang R., Synergy between an antiangiogenic integrin αv antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases Proceedings of the National Academy of Sciences of the United States of America 1999 96 4 1591 1596
32. Klement G., Baruchel S., Rak J., Continous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without over toxicity The Journal of Clinical Investigation 2000 105 8 15 24
33. Erdreich-Epstein A., Shimada H., Groshen S., Integrins αv β3 and αv β5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide Cancer Research 2000 60 3 712 721
34. Evans A. E., Kisselbach K. D., Yamashiro D. J., Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts Clinical Cancer Research 1999 5 11 3594 3602
35. Evans A. E., Kisselbach K. D., Liu X., Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB Medical and Pediatric Oncology 2001 36 1 181 184
36. Ho R., Minturn J. E., Hishiki T., Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor Cancer Research 2005 65 21 9868 9875
37. Beppu K., Jaboine J., Merchant M. S., Mackall C. L., Thiele C. J.
38. Vitali R., Cesi V., Nicotra M. R., c-Kit is preferentially expressed in MYCN -amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571 International Journal of Cancer 2003 106 2 147 152
39. Melino G., Draoui M., Bellincampi L., Retinoic acid receptors α and γ mediate the induction of "tissue" transglutaminase activity and apoptosis in human neuroblastoma cells Experimental Cell Research 1997 235 1 55 61
40. Voigt A.
41. Reynolds C. P.
42. Garaventa A.
43. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocrine Reviews 1999 20 5 649 688
44. Reginato M. J., Krakow S. L., Bailey S. T., Lazar M. A., Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor γ Journal of Biological Chemistry 1998 23 273 1855 1858
45. Juge-Aubry C., Pernin A., Favez T., DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements: importance of the 5′ -flanking region Journal of Biological Chemistry 1997 272 40 25252 25259
46. Grommes C., Landreth G. E., Heneka M. T.
47. Tontonoz P., Singer S., Forman B. M., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor Proceedings of the National Academy of Sciences of the United States of America 1997 94 1 237 241
48. Konopleva M., Elstner E., McQueen T. J., Peroxisome proliferator- activated receptor γ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias Molecular Cancer Therapeutics 2004 3 10 1249 1262
49. Yamazaki K., Shimizu M.
50. Avis I., Martínez A., Tauler J., Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition Cancer Research 2005 65 10 4181 4190
51. Crowe D. L., Chandraratna R. A. S., A retinoid X receptor (RXR)-selective retinoid reveals that RXR- α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responsive to peroxisome proliferator-activated receptor ligands Breast Cancer Research 2004 6 5 R546 R555
52. Burdge G. C., Rodway H., Kohler J. A., Lillycrop K. A.
53. Di Loreto S., D'Angelo B., D'Amico M. A., PPAR β agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y Journal of Cellular Physiology 2007 211 3 837 847
54. Han S. W., Greene M. E., Pitts J., Wada R. K., Sidell N., Novel expression and function of peroxisome proliferator-activated receptor γ (PPAR γ) in human neuroblastoma cells Clinical Cancer Research 2001 7 1 98 104
55. Sato Y., Sasaki H., Kobayashi Y., Expression of PPAR-gamma is correlated with the clinical course of neuroblastoma Journal of Pediatric Surgery 2003 38 2 205 210
56. Nakagawara A., Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities Human Cell 1998 11 3 115 124
57. Yamamoto K.
58. Yoneda A., Oue T., Imura K., Observation of untreated patients with neuroblastoma dected by mass screening: a "wait and see" pilot study Medical and Pediatric Oncology 2001 36 1 160 162
59. Fukushima M., Biological activities and mechanisms of action of PGJ2 and related compounds: an update Prostaglandins, Leukotrienes and Essential Fatty Acids 1992 47 1 1 12
60. Rohn T. T., Wong S. M., Cotman C. W., Cribbs D. H., 15-deoxy- Δ12,14 -prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor- γ, induces neuronal apoptosis NeuroReport 2001 12 4 839 843
61. Kim E. J., Park K. S., Chung S. Y., Peroxisome proliferator-activated receptor- γ activator 15-deoxy- Δ12,14 -prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway Journal of Pharmacology and Experimental Therapeutics 2003 307 2 505 517
62. Rodway H. A., Hunt A. N., Kohler J. A., Postle A. D., Lillycrop K. A.
63. Eichholtz T., Jalink K., Fahrenfort I., Moolenaar W. H., The bioactive phospholipid lysophosphatidic acid is released from activated platelets Biochemical Journal 1993 291, part 3 677 680
64. Yatomi Y.
65. Jung K. M., Park K. S., Oh J. H., Activation of p38 mitogen-activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy- Δ12,14 -prostaglandin J2 Molecular Pharmacology 2003 63 3 607 616
66. Han S., Wada R. K., Sidell N., Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor γ Cancer Research 2001 61 10 3998 4002
67. Valentiner U.
68. Emmans V. C., Rodway H. A., Hunt A. N., Lillycrop K. A.
69. Kato M., Nagaya T., Fujieda M., Saito K., Yoshida J., Seo H., Expression of PPAR γ and its ligand-dependent growth inhibition in human brain tumor cell lines Japanese Journal of Cancer Research 2002 93 6 660 666
70. Schultze K., Böck B., Eckert A., Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin Apoptosis 2006 11 9 1503 1512
71. Jung T. W., Lee J. Y., Shim W. S., Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity Biochemical and Biophysical Research Communications 2006 340 1 221 227
72. Jung T. W., Lee J. Y., Shim W. S., Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production Journal of the Neurological Sciences 2007 253 1-2 53 60
73. Servidei T.
74. Cellai I., Benvenuti S., Luciani P., Antineoplastic effects of rosiglitazone and PPAR γ transactivation in neuroblastoma cells British Journal of Cancer 2006 95 7 879 888
75. Sugiura Y., Shimada H., Seeger R. C., Laug W. E., DeClerck Y. A.
76. Chantrain C. F., Shimada H., Jodele S., Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment Cancer Research 2004 64 5 1675 1686
77. Ogita S., Tokiwa K., Arizono N., Takahashi T., Neuroblastoma: incomplete differentiation on the way to maturation or morphological alteration resembling maturity? Oncology 1988 45 3 148 152
78. Shao D., Lazar M. A., Modulating nuclear receptor function: may the phos be with you Journal of Clinical Investigation 1999 103 12 1617 1618